Black Rock Inc. Cyteir Therapeutics, Inc. Transaction History

Black Rock Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$2.84 - $3.13 $17,022 - $18,761	5,994 Added 7.0%	91,578 $278,000
Q3 2023 Nov 13, 2023	SELL	$2.71 - $2.84 $7,650 - $8,017	-2,823 Reduced 3.19%	85,584 $243,000
Q2 2023 Aug 11, 2023	BUY	$1.74 - $2.6 $12,460 - $18,618	7,161 Added 8.81%	88,407 $229,000
Q1 2023 May 12, 2023	BUY	$1.47 - $1.84 $2,795 - $3,499	1,902 Added 2.4%	81,246 $147,000
Q4 2022 Feb 13, 2023	SELL	$1.18 - $1.76 $138,730 - $206,919	-117,568 Reduced 59.71%	79,344 $130,000
Q3 2022 Nov 14, 2022	SELL	$1.99 - $4.05 $9,138 - $18,597	-4,592 Reduced 2.28%	196,912 $376,000
Q2 2022 Aug 12, 2022	SELL	$1.62 - $4.4 $750,452 - $2.04 Million	-463,242 Reduced 69.69%	201,504 $601,000
Q1 2022 May 12, 2022	BUY	$3.39 - $10.51 $414,678 - $1.29 Million	122,324 Added 22.55%	664,746 $2.51 Million
Q4 2021 Feb 10, 2022	BUY	$9.83 - $19.21 $1.48 Million - $2.9 Million	151,023 Added 38.59%	542,422 $6.17 Million
Q3 2021 Nov 09, 2021	BUY	$14.57 - $21.86 $5.7 Million - $8.56 Million	391,399 New	391,399 $6.87 Million

2.47M

Ticker CYT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,413,400
Market Cap $107M
Description
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for c...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.